Okay, let's tackle this question. The patient is a 59-year-old male with a hemoglobin level of 18.0 gm/dl on three occasions. The resident wants to exclude Polycythemia Vera (PV). I need to figure out the most relevant investigation for this.

First, I remember that Polycythemia Vera is a myeloproliferative neoplasm characterized by an increased red blood cell mass. The key here is that the hemoglobin is consistently high. But there are other causes of secondary polycythemia, like chronic hypoxia or smoking. So, the main goal is to differentiate between PV and secondary causes.

The core concept here is that PV is a clonal disorder, so we need to look for markers of clonality. One of the hallmark tests for PV is the JAK2 mutation analysis. The JAK2 V617F mutation is present in a high percentage of PV cases. If this mutation is found, it strongly supports the diagnosis of PV.

Now, looking at possible options. The correct answer here should be JAK2 mutation testing. Let me think about other options. For example, maybe CBC, peripheral smear, or serum erythropoietin levels. But CBC would show increased RBCs, Hb, Hct, but that's not specific. Peripheral smear might show teardrop cells in myelofibrosis, but not PV. Serum EPO levels in PV are usually low because the body doesn't need to produce more EPO since there are already too many RBCs. So low EPO would suggest PV, while normal or high EPO might indicate secondary causes.

Wait, the question is asking for the most relevant investigation to exclude PV. So if the JAK2 test is positive, then PV is confirmed. If negative, other tests might be needed. But JAK2 mutation is a key diagnostic marker. The other options like CBC or EPO levels are part of the workup but not the most specific. So the answer is JAK2 mutation analysis.

Let me check again. The options were A to D but not listed. The correct answer is probably D, assuming the options include JAK2. The resident needs to check for the JAK2 mutation to confirm or exclude PV. The clinical pearl here is that JAK2 mutation is a high-yield fact for PV diagnosis. Also, remember that PV is part of the myeloproliferative neoplasms along with essential thrombocythemia and myelofibrosis. So the correct answer is JAK2 mutation testing.

**Core Concept**
Polycythemia Vera (PV) is a clonal myeloproliferative neoplasm characterized by overproduction of red blood cells. Diagnosis requires evidence of increased red cell mass, exclusion of secondary causes, and identification of clonality via **JAK2 V617F mutation analysis**.

**Why the Correct Answer is Right**
The **JAK2 V617F mutation** is present in 95% of PV cases, confirming clonal erythrocytosis. PV arises from a hematopoietic stem cell mutation, leading to autonomous RBC proliferation independent of erythropoietin (EPO). Testing for this mutation is critical to distinguish PV from secondary polycythemia (e.g.,

✓ Correct Answer: C. Red cell mass